

# Medication Adherence for Diabetes Guide

## Effective January 2025

This measure tracks the percentage of Medicare Part D beneficiaries aged 18 and older who consistently adhere to their prescribed diabetes medication regimen. To be included in the measure, patients must have at least two separate prescription fills for non-insulin diabetes medications, using their Part D benefit, during the measurement period. To close the gap, the patient must maintain a medication adherence rate measured by prescription fill history that covers at least 80% of days within the measurement year, regardless of the total prescribed therapy duration.

Note: Only prescription drug claims are used to determine both eligibility and adherence for this measure.

Key Factors	Formulary Medications	
Who's Included in the Measure	Patients taking medications in the following drug classes are included in the measure: biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, GIP/GLP-1 receptor agonists, meglitinides, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. (See the Formulary Medications section for a list of formulary medications.)	
	Measure qualification is based solely on prescription drug claims, not on medical diagnosis codes. This means that even if a patient does not have a diabetes diagnosis, they are included in the measure if they take a medication listed in the "Formulary Medications" chart on the following page.	
Exclusions	• In hospice	
	ESRD diagnosis or dialysis coverage dates	
	One or more prescriptions for insulin	
Metformin	Over 60% of Blue Advantage® members taking metformin are considered non-adherent.	
	When initiating metformin therapy, consider prescribing the extended-release (ER) formulation to help reduce gastrointestinal side effects.	
	For formulary coverage at no cost to the member, prescribe generic Glucophage XR 500 mg or 750 mg* and sign for product selection permitted. <b>Note:</b> Some plans may require the use of a preferred pharmacy to qualify for a \$0 copay.	
Writing the Prescription	Write initial prescription to dispense no more than a 30-day supply at a time.	
	Follow-Up and Maintenance Recommendations:	
	<ul> <li>Schedule a follow-up visit within 30 days to assess dose effectiveness and address any barriers to adherence (e.g., side effects, cost).</li> </ul>	
	<ul> <li>Once patients demonstrate tolerance and benefit from therapy, adjust the maintenance prescription to allow up to a 100-day supply through their retail or mail-order pharmacy.</li> </ul>	
	<ul> <li>Ensure prescriptions are written or updated to reflect how the patient is taking the medication especially when changing the dose or frequency prescribed.</li> </ul>	
	Reinforce the importance of taking medications as prescribed.	
	Remind patients to contact their provider if they experience any adverse effects.	
Controlling Blood Sugar	Help patients connect their medication use with expected outcomes, as measured by regular blood glucose monitoring.	
	<ul> <li>Prescribe preferred products (see the Formulary Medications section for a list) through a pharmacy for \$0 patient cost-share.</li> </ul>	
	Discuss the benefits of blood sugar control and review each patient's target values.	
	Educate patients on the role of exercise and healthy eating in managing blood glucose levels.	

PRV20814PAT-2507 1 of 4

# **Coverage Resources for Blue Advantage Diabetes Patient**

Formulary Medications				
Drug Class	Medication			
<b>Biguanide</b> Expected hemoglobin A1C reduction of 1% - 2%	metformin			
	glimepiride			
Sulfonylureas Expected hemoglobin A1C reduction up to 1% - 2%	glipizide			
	glyburide*			
Thiazolidinedione Expected hemoglobin A1C reduction up to 1.5%	pioglitazone			
Meglitinides	nateglinide			
Expected hemoglobin A1C reduction up to 1.5%	repaglinide			
	glipizide/metformin			
Combination Medications	glyburide/metformin**			
Gombination Medications	pioglitazone/glimepiride**			
	pioglitazone/metformin**			
	Bydureon* (exenatide XR)			
GLP-1* Expected hemoglobin A1C reduction up to 1.5%	Mounjaro* (tirzepatide)			
Medications in this category require confirmation of a diabetes	Ozempic* (semaglutide)			
diagnosis for coverage.	Rybelsus* (semaglutide)			
	Trulicity* (dulaglutide)			
	Farxiga* (dapagliflozin)			
	Glyxambi* (empagliflozin/linagliptin)			
SGLT2*	Jardiance* (empagliflozin)			
Expected hemoglobin A1C reduction up to 1%	Synjardy* (empagliflozin/metformin)			
	Synjardy XR* (empagliflozin/metformin XR)			
	Xigduo XR* (dapagliflozin/metformin XR)			
	Januvia* (sitagliptin)			
	Janumet* (sitagliptin/metformin)			
DPP-4*	Janumet XR* (sitagliptin/metformin XR)			
Expected hemoglobin A1C reduction up to 1%	Jentadueto* (linagliptin/metformin)			
	Jentadueto XR* (linagliptin/metformin XR)			
	Tradjenta* (linagliptin)			

<sup>\*</sup>These medications have a higher cost share.

<sup>\*\*</sup>Combination drugs may carry a higher cost share. To reduce costs, consider prescribing components of combination drugs separately.

## **Prescribing Deep Dive**

Formulary Medications with Cardiovascular Benefits	Formulary Medications with Heart Failure Benefits	Formulary Medications with Chronic Kidney Disease Benefits
Jardiance (empagliflozin) Ozempic (semaglutide) Trulicity (dulaglutide)	Farxiga (dapagliflozin) Jardiance (empagliflozin) Synjardy (empagliflozin/metformin) Synjardy XR (empagliflozin/metformin XR) Xigduo XR (dapagliflozin/metformin XR)	Farxiga (dapagliflozin) Glyxambi (empagliflozin-linagliptin) Jardiance (empagliflozin) Synjardy (empagliflozin/metformin) Synjardy XR (empagliflozin/metformin XR) Xigduo XR (dapagliflozin/metformin XR)

Average Impact on Weight				
TZD - gain (up to 11 kg)	DPP-4 – neutral			
Sulfonylureas – gain (2 to 5 kg)	SGLT2 – loss (2 to 4 kg)			
Metformin – neutral	GLP-1 – loss (2 to 5 kg)			

Possible Hypoglycemia Risk		
Sulfonylureas – high risk		
GLP-1/SGLT2/DPP-4 – low risk		
Metformin/TZD – none		

**DPP-4** = Dipeptidyl peptidase-4 inhibitors

**SGLT2** = Sodium-glucose cotransporter 2 inhibitors

**GLP-1** = Glucagon-like peptide 1 agonists

**TZD** = Thiazolidinediones

**Note:** One prescription fill of any insulin within the measurement period will remove a patient from the diabetes adherence measure.

Formulary Insulins				
Humulin 70/30 KwikPen, Vial	Novolin 70/30 FlexPen, Vial*			
Humulin N and R KwikPen, Vial	Novolin N and R FlexPen, Vial*			
Humulin R U-500 (Concentrated) KwikPen, Vial	NovoLog 70/30 FlexPen, Vial*			
Humalog Cartridge, KwikPen, Junior KwikPen, Tempo Pen, Vial	NovoLog FlexPen, PenFill, Vial*			
Humalog Mix 50/50 and 75/25 KwikPen, Vial	Soliqua 100/33 Pen			
Lantus SoloStar, Vial	Toujeo SoloStar			
Lyumjev KwikPen, Tempo Pen, Vial	Toujeo Max SoloStar			

**Note:** All formulary insulins have a quantity limit of six vials or 20 pens/cartridges for a 30-day supply. \*ReliOn version is also on formulary.

Duration of Insulin Therapy Prescriptions	Standard Pharmacy	Preferred Pharmacy
30-day supply	\$35	\$35
60-day supply	\$70	\$70
Up to 100-day supply	\$105	\$70*

<sup>\*</sup>Patients save on 100 day-supply of insulin when using a Preferred Pharmacy.

#### **Blood Sugar Monitoring**

**\$0** Diabetic Testing supplies (meters and test strips) obtained through the pharmacy are limited to Ascensia products (e.g., Contour) and LifeScan products (e.g., OneTouch).

**Prior approval** will be required for any other brands of meters and test strips. Must try and fail two preferred products before PA can be approved.

All test strips will be subject to a quantity limit of **204 per 30 days**. There are **no quantity limits** on lancets

**\$0 CGM Products** obtained through the pharmacy are limited to Medicare-covered **Dexcom** products and Abbott **Freestyle** products.

**Prior approval** will be required for any other CGM brands. Must try and fail one preferred product before PA can be approved. Receivers and transmitters are subject to quantity limits (i.e., **one receiver per calendar year**, one transmitter **every 90 days**, and sensors per product labeling).

**Note:** If obtaining diabetic testing supplies or a CGM products from a durable medical equipment (DME) supplier, standard DME benefits apply.

#### Adherence Resources

#### Home Delivery/Mail Order Pharmacies

#### **Amazon Pharmacy**

► E-scribe: Amazon Pharmacy Home Delivery

**Fax:** 512-677-6267

▶ Address: 4500 S Pleasant Valley Rd., Suite 201

Austin, TX 78744

#### **Walgreens Mail Service**

► E-scribe: Walgreens Mail Service: NCPDP 0320793

Fax: 1-800-215-6612Call: 1-800-345-1036

#### **Express Scripts Pharmacy**

► E-scribe: Express Scripts Home Delivery

**Fax:** 1-800-837-0959

**Call:** 1-888-327-9791, Option 2

Note: Express Scripts will not fill GLP1s.

### **Dose Packaging Services\***

#### **ExactCare Pharmacy**

► E-scribe: Search ExactCare Pharmacy by zip code 44125

**Fax:** 1-855-355-3480

**Call:** 1-877-355-7225, opt. 2

▶ Address: 8333 Rockside Road, Valley View, OH 44125

#### **PillPack by Amazon Pharmacy**

► E-scribe: PILLPACK LLC, DBA PillPack by Amazon

Address: 250 Commercial Street, Suite 2012

Manchester, NH 03101

\*Limited to 30-day supplies. No cost savings available for 90-day supplies with this option.



Blue Advantage® PPO is provided by Patrius Health, an independent licensee of the Blue Cross and Blue Shield Association.

Blue Advantage is a PPO with a Medicare contract. Enrollment in Blue Advantage (PPO) depends on CMS contract renewal.

Walgreens Mail Service is an independent pharmacy providing mail-order pharmacy services to Patrius Health members.

Amazon Pharmacy is an independent pharmacy providing mail-order pharmacy services to Patrius Health members.

ExactCare is an independent company providing in-home medication management services and support to Patrius Health members.

Express Scripts Inc. is an independent company contracted to provide pharmacy benefit management services.

PillPack, Inc., an Amazon company, is an independent online pharmacy which packages and delivers medications to Patrius Health members.

PRV20814PAT-2508 4 of 4